Dr Jacques Servier founded Servier in France in 1954 and led his company to its established global presence today. Of the current 20,000 personnel in 140 countries, 3,000 are in research and development, reflecting a focus on this priority. In an interview with the French broadsheet newspaper, Le Figaro, Dr Servier revealed that all profit from Servier worldwide operations is now channeled into research and development projects. This policy builds on a longstanding company strategy of maintaining R&D investment at or above 25 per cent of consolidated turnover – well above the industry average – a strategy allowed by the company’s independent status and freedom from competing shareholder interests.
Servier’s current research approach focuses on new first-in-class chemical entities – generating extensive intellectual property. This means the company’s research and development is at the high end of pharmaceutical innovation and intrinsically carries the highest level of technical risk.
A consistent focus on research has led to a prolific output of more than 47,000 compounds protected by 25,000 patents. It has also meant commercial success – with global turnover of 3.6 billion Euros in 2009, 86% percent outside the home French market.
print
Dr Jacques Servier founded Servier in France in 1954 and led his company to its established global presence today. Of the current 20,000 personnel in 140 countries, 3,000 are in research and development, reflecting a focus on this priority. In an interview with the French broadsheet newspaper, Le Figaro, Dr Servier revealed that all profit from Servier worldwide operations is now channeled into research and development projects. This policy builds on a longstanding company strategy of maintaining R&D investment at or above 25 per cent of consolidated turnover – well above the industry average – a strategy allowed by the company’s independent status and freedom from competing shareholder interests.